Literature DB >> 16553034

Non-alcoholic fatty liver disease is associated with carotid artery wall thickness in diet-controlled type 2 diabetic patients.

G Targher1, L Bertolini, R Padovani, F Poli, L Scala, L Zenari, G Zoppini, G Falezza.   

Abstract

Non-alcoholic fatty liver disease (NAFLD) is closely associated with several metabolic syndrome (MetS) features. We assessed whether NAFLD is significantly associated with carotid artery intima-media thickness (IMT), as a marker of subclinical atherosclerosis, and whether such association is independent of classical cardiovascular risk factors and MetS features. We studied 100 diet-controlled Type 2 diabetic patients with ultrasonographically diagnosed NAFLD and 100 diabetic patients without NAFLD who were comparable for age and sex. Main outcome measures were carotid IMT (by ultrasonography), classical risk factors, insulin resistance [as estimated by homeostasis model assessment (HOMA)-IR] and MetS (as defined by the Adult Treatment Panel III criteria). NAFLD patients had a markedly greater carotid IMT (1.24 +/- 0.13 vs 0.95 +/- 0.11 mm; p < 0.001) than those without the condition. The MetS and all its clinical traits were more highly prevalent in those with NAFLD (p < 0.001). Adjustment for age, sex, smoking history, diabetes duration, glycosylated hemoglobin, LDL cholesterol, liver enzymes and microalbuminuria did not really affect the significant differences in carotid IMT that were observed between the groups. Further adjustment for the MetS also had little impact, but additional adjustment for HOMA-IR score consistently attenuated any statistical significance (p = 0.28). In multivariate regression analysis, HOMA-IR score along with age and MetS (principally raised blood pressure values) were independently related to carotid IMT, whereas NAFLD was not. In conclusion, these results suggest that among diet-controlled Type 2 diabetic individuals the significant increase of carotid IMT in the presence of NAFLD is largely explained by HOMA-estimated insulin resistance.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16553034     DOI: 10.1007/BF03349177

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  23 in total

Review 1.  Nonalcoholic fatty liver disease.

Authors:  Paul Angulo
Journal:  N Engl J Med       Date:  2002-04-18       Impact factor: 91.245

2.  Non-alcoholic hepatic steatosis and its relation to increased plasma biomarkers of inflammation and endothelial dysfunction in non-diabetic men. Role of visceral adipose tissue.

Authors:  G Targher; L Bertolini; L Scala; G Zoppini; L Zenari; G Falezza
Journal:  Diabet Med       Date:  2005-10       Impact factor: 4.359

3.  Cardiovascular morbidity and mortality associated with the metabolic syndrome.

Authors:  B Isomaa; P Almgren; T Tuomi; B Forsén; K Lahti; M Nissén; M R Taskinen; L Groop
Journal:  Diabetes Care       Date:  2001-04       Impact factor: 19.112

Review 4.  Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome.

Authors:  B L Wajchenberg
Journal:  Endocr Rev       Date:  2000-12       Impact factor: 19.871

5.  Dietary habits and their relations to insulin resistance and postprandial lipemia in nonalcoholic steatohepatitis.

Authors:  Giovanni Musso; Roberto Gambino; Franco De Michieli; Maurizio Cassader; Mario Rizzetto; Marilena Durazzo; Emanuela Fagà; Barbara Silli; Gianfranco Pagano
Journal:  Hepatology       Date:  2003-04       Impact factor: 17.425

6.  Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome.

Authors:  Giulio Marchesini; Elisabetta Bugianesi; Gabriele Forlani; Fernanda Cerrelli; Marco Lenzi; Rita Manini; Stefania Natale; Ester Vanni; Nicola Villanova; Nazario Melchionda; Mario Rizzetto
Journal:  Hepatology       Date:  2003-04       Impact factor: 17.425

7.  Intimal-medial thickness of the carotid artery in nondiabetic and NIDDM patients. Relationship with insulin resistance.

Authors:  E Bonora; R Tessari; R Micciolo; M Zenere; G Targher; R Padovani; G Falezza; M Muggeo
Journal:  Diabetes Care       Date:  1997-04       Impact factor: 19.112

8.  Beyond insulin resistance in NASH: TNF-alpha or adiponectin?

Authors:  Jason M Hui; Alex Hodge; Geoffrey C Farrell; James G Kench; Adamandia Kriketos; Jacob George
Journal:  Hepatology       Date:  2004-07       Impact factor: 17.425

9.  Systemic levels of lipid peroxidation and its metabolic and dietary correlates in patients with nonalcoholic steatohepatitis.

Authors:  Naga Chalasani; Mark A Deeg; David W Crabb
Journal:  Am J Gastroenterol       Date:  2004-08       Impact factor: 10.864

10.  The Metabolic Syndrome is an independent predictor of cardiovascular disease in Type 2 diabetic subjects. Prospective data from the Verona Diabetes Complications Study.

Authors:  E Bonora; G Targher; G Formentini; F Calcaterra; S Lombardi; F Marini; L Zenari; F Saggiani; M Poli; S Perbellini; A Raffaelli; L Gemma; L Santi; R C Bonadonna; M Muggeo
Journal:  Diabet Med       Date:  2004-01       Impact factor: 4.359

View more
  29 in total

1.  Association between nonalcoholic fatty liver disease and carotid atherosclerosis: a meta-analysis.

Authors:  Jia Cai; Shujun Zhang; Wenxiang Huang
Journal:  Int J Clin Exp Med       Date:  2015-05-15

Review 2.  Nonalcoholic fatty liver disease and cardiovascular disease risk.

Authors:  Roger K Schindhelm; Michaela Diamant; Robert J Heine
Journal:  Curr Diab Rep       Date:  2007-06       Impact factor: 4.810

Review 3.  NAFLD/NASH in patients with type 2 diabetes and related treatment options.

Authors:  M G Radaelli; F Martucci; S Perra; S Accornero; G Castoldi; G Lattuada; G Manzoni; G Perseghin
Journal:  J Endocrinol Invest       Date:  2017-11-30       Impact factor: 4.256

4.  Ultrasound Diagnosis of Hepatic Steatosis as a Surrogate for Atherosclerosis.

Authors:  S Guth; E Windler; U Leise; C M Bamberger
Journal:  Ultrasound Int Open       Date:  2016-03-01

Review 5.  Obstructive sleep apnea syndrome and fatty liver: association or causal link?

Authors:  Mohamed-H Ahmed; Christopher-D Byrne
Journal:  World J Gastroenterol       Date:  2010-09-14       Impact factor: 5.742

Review 6.  Pediatric nonalcoholic fatty liver disease, metabolic syndrome and cardiovascular risk.

Authors:  Lucia Pacifico; Valerio Nobili; Caterina Anania; Paola Verdecchia; Claudio Chiesa
Journal:  World J Gastroenterol       Date:  2011-07-14       Impact factor: 5.742

Review 7.  Risk of cardiovascular disease and chronic kidney disease in diabetic patients with non-alcoholic fatty liver disease: just a coincidence?

Authors:  G Targher; M Chonchol; I Pichiri; G Zoppini
Journal:  J Endocrinol Invest       Date:  2011-03-21       Impact factor: 4.256

Review 8.  Increased risk of cardiovascular disease in non-alcoholic fatty liver disease: causal effect or epiphenomenon?

Authors:  G Targher; F Marra; G Marchesini
Journal:  Diabetologia       Date:  2008-09-02       Impact factor: 10.122

9.  Plasminogen activator inhibitor-1 and thrombin activatable fibrinolysis inhibitor levels in non-alcoholic steatohepatitis.

Authors:  S Yener; M Akarsu; T Demir; B Akinci; O Sagol; F Bayraktar; M A Ozcan; E Tankurt; S Yesil
Journal:  J Endocrinol Invest       Date:  2007-11       Impact factor: 4.256

10.  Nonalcoholic fatty liver disease is a novel predictor of cardiovascular disease.

Authors:  Masahide Hamaguchi; Takao Kojima; Noriyuki Takeda; Chisato Nagata; Jun Takeda; Hiroshi Sarui; Yutaka Kawahito; Naohisa Yoshida; Atsushi Suetsugu; Takahiro Kato; Junichi Okuda; Kazunori Ida; Toshikazu Yoshikawa
Journal:  World J Gastroenterol       Date:  2007-03-14       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.